drugset / Trial / NCT00217386
Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes
Phase 2
Completed
30 enrolled
Fred Hutchinson Cancer Center
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: Biological therapies, such as anti-thymocyte globulin and etanercept, may stimulate the immune system in different ways and stop cancer cells from growing. Giving anti-thymocyte globulin together with etanercept may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving anti-thymocyte globulin together with etanercept works in treating patients with myelodysplastic syndromes.
Timeline
- Start
- 2004-03
- Primary completion
- 2007-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | Intravenous |
| Subject | Etanercept | Protein / enzyme biologic | — | Subcutaneous |